Envudeucitinib Clinical Trials (2026): 6 Studies for Plaque Psoriasis & Moderate Psoriasis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 Envudeucitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Plaque Psoriasis & Moderate Psoriasis) and 4,059 total planned enrollment. 3 Phase 3 Envudeucitinib trials and 2 Phase 2 are listed. Most recent activity: NCT06846541 (Nov 2028).
Envudeucitinib clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P2 | 2 | 2 | |
| P3 | 1 | 2 | 3 |
Envudeucitinib clinical trials by indication
Plaque Psoriasis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06846541 | ONWARD3 | P3 | active not recruiting | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis |
| NCT05739435 | — | P2 | active not recruiting | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis |
| NCT06588738 | ONWARD2 | P3 | completed | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 |
| NCT06586112 | ONWARD1 | P3 | completed | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis |
Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06952634 | — | P1 | completed | An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage |
SLE (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05966480 | LUMUS | P2 | active not recruiting | Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus |
Envudeucitinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ONWARD3 | NCT06846541 | P3 | active not recruiting | Plaque Psoriasis | 1,680 | — |
| ONWARD2 | NCT06588738 | P3 | completed | Plaque Psoriasis | 862 | — |
| ONWARD1 | NCT06586112 | P3 | completed | Plaque Psoriasis | 912 | — |
| LUMUS | NCT05966480 | P2 | active not recruiting | SLE | 408 | — |
All Envudeucitinib trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06846541 | ONWARD3 | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | P3 | active not recruiting | 1,680 | Alumis Inc | Jan 2025 |
| NCT05966480 | LUMUS | Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus | P2 | active not recruiting | 408 | Alumis Inc | Jun 2023 |
| NCT05739435 | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis | P2 | active not recruiting | 165 | Alumis Inc | Jan 2023 | |
| NCT06952634 | An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage | P1 | completed | 32 | Alumis Inc | Apr 2025 | |
| NCT06588738 | ONWARD2 | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 | P3 | completed | 862 | Alumis Inc | Aug 2024 |
| NCT06586112 | ONWARD1 | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis | P3 | completed | 912 | Alumis Inc | Jul 2024 |
Envudeucitinib clinical trials: frequently asked questions
- How many Envudeucitinib clinical trials are there?
- 6 Envudeucitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are marked completed.
- Are Envudeucitinib clinical trials recruiting in 2026?
- No active Envudeucitinib trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Envudeucitinib being studied for?
- Envudeucitinib is being studied for Plaque Psoriasis, Moderate Psoriasis, Hepatic Impairment, Psoriasis (PsO), Severe Psoriasis and 2 more. The trials are grouped by indication on this page.
- What phase is Envudeucitinib in?
- Envudeucitinib clinical trials span 3 Phase 3, 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Envudeucitinib clinical trials?
- The lead sponsor across the most Envudeucitinib trials is Alumis Inc. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Envudeucitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: